US equities
|
NVDA
$236.72
▲+1.19%
SPCX
$166.75
▲+4.90%
MU
$1,066.84
▼-0.75%
TSLA
$377.67
▲+1.91%
MSFT
$526.91
▲+1.81%
INTC
$117.23
▼-1.76%
SNDK
$1,731.33
▲+0.66%
META
$742.83
▲+2.03%
NVDA
$236.72
▲+1.19%
SPCX
$166.75
▲+4.90%
MU
$1,066.84
▼-0.75%
TSLA
$377.67
▲+1.91%
MSFT
$526.91
▲+1.81%
INTC
$117.23
▼-1.76%
SNDK
$1,731.33
▲+0.66%
META
$742.83
▲+2.03%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Oragenics Inc. Common Stock
(NY:
OGEN
)
0.4861
-0.0039 (-0.80%)
Delayed Quote
Updated: 9:51 AM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Oragenics Inc. Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) to Present ONP-002 Concussion Program at IPAC-RS 2026 Nasal Innovation Forum
September 16, 2026
Via
Investor Brand Network
NetworkNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Advances Phase IIa Concussion Trial, Provides FDA and Listing Updates
August 31, 2026
Via
Investor Brand Network
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Activates All Australian Phase IIa Trial Sites for ONP-002
July 07, 2026
Via
Investor Brand Network
Sidoti Events, LLC's May Micro-Cap Virtual Conference
May 20, 2026
Via
ACCESS Newswire
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) to Present at Sidoti Micro-Cap Virtual Investor Conference
May 19, 2026
Via
Investor Brand Network
BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Highlights Phase IIa Progress and Strategic CNS Expansion Plans
May 18, 2026
Via
Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Signs LOI to License CardioDialysis Technology From Sigyn Therapeutics
May 07, 2026
Via
Investor Brand Network
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Advances Phase IIa Trial Enrollment For Concussion Treatment Candidate
May 05, 2026
Via
Investor Brand Network
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Reports Early Dosing Progress in Phase IIa Trial of Intranasal Concussion Therapy
April 20, 2026
Via
Investor Brand Network
BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Doses First Patient in Phase IIa Trial of Concussion Treatment
April 13, 2026
Via
Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Reports Going Concern Audit Opinion Disclosure
March 26, 2026
Via
Investor Brand Network
TinyGemsBreaks – Oragenics Inc. (NYSE American: OGEN) Files 2025 Form 10-K And Provides Operational Update
March 17, 2026
Via
Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Initiates First Clinical Site for Phase IIa Trial of ONP-002 in Australia
March 12, 2026
Via
Investor Brand Network
BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Explores CNS Asset Acquisitions To Expand Brain Health Pipeline
March 11, 2026
Via
Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Receives Australian Ethics Approval to Launch Phase IIa Concussion Trial
March 10, 2026
Via
Investor Brand Network
BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Previews 2026 Milestones for Intranasal Concussion Therapeutic ONP-002
February 09, 2026
Via
Investor Brand Network
BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Engages DUCK FLATS Pharma for IND Readiness and Regulatory Execution
February 03, 2026
Via
Investor Brand Network
BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Participates in SCOPE Summit 2026 Ahead of Phase 2a Concussion Trial
February 02, 2026
Via
Investor Brand Network
BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) to Present at Sequire Investor Summit 2026
January 14, 2026
Via
Investor Brand Network
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Regains NYSE Compliance, Advances Toward First Clinical Trial and Expands AI-Driven Neurology Pipeline
November 12, 2025
Via
Investor Brand Network
Topics
Artificial Intelligence
Oragenics Q3 2025 Shareholder Update
November 12, 2025
From
Oragenics, Inc.
Via
Business Wire
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Regains NYSE Compliance, Strengthens Balance Sheet for Clinical Advancement
October 21, 2025
Via
Investor Brand Network
Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
October 21, 2025
From
Oragenics, Inc.
Via
Business Wire
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Partners with Receptor.AI to Accelerate AI-Driven Discovery of Brain-Targeted Therapeutics
October 07, 2025
Via
Investor Brand Network
Topics
Artificial Intelligence
Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development
October 07, 2025
From
Oragenics
Via
Business Wire
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Highlights Q2 2025 Progress and Prepares for Phase IIa Concussion Trial
August 11, 2025
Via
Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Selects Southern Star Research as CRO for Phase IIa Trial of Intranasal Concussion Therapy ONP-002
July 31, 2025
Via
Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Secures U.S. Manufacturing Partner Ahead of Phase IIb Trials for Concussion Drug
July 16, 2025
Via
Investor Brand Network
12 Health Care Stocks Moving In Monday's After-Market Session
↗
July 07, 2025
Via
Benzinga
Monday's after hours session: top gainers and losers
↗
July 07, 2025
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
Next >
